Numerous studies have detected a greater likelihood of excess weight gain with specific
antiretrovirals (ARVs), particularly tenofovir alafenamide and integrase inhibitors, as …

Life expectancy of people living with HIV (PLWH) is now close to that of the HIV-uninfected
population. As a result, age-related comorbidities, including osteoporosis, are increasing in …

Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Background Updated WHO guidelines recommend a dolutegravir-based regimen as the
preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an …

Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

Background Integrase strand transfer inhibitors (INSTIs) have been associated with an
increased risk for cardiovascular disease (CVD) events. We investigated the impact of …

Background De novo steatosis is the main criteria for non-alcoholic fatty liver disease
(NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This …

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+
dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+ DTG, or TDF/FTC/efavirenz …

Background & Aims It remains unknown whether tenofovir alafenamide (TAF) could replace
tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV) …

Background Weight gain effects of individual antiretroviral drugs are not fully understood.
We investigated associations between a prespecified clinically significant increase (> 7%) in …